Nasal Delivery Redefines Immunity: Fighting Melanoma Brain Metastases with a Cancer Nanovaccine
Tuesday, July 15, 2025
10:54 AM - 11:05 AM EDT
Location: 119 B
Introduction: Despite advancements with immune checkpoint inhibitors for metastatic melanoma, their benefits are limited to a small percentage of patients, with many experiencing immune-mediated side effects or disease relapse [1]. These challenges stem from tumor-driven immunosuppression and poor T cell infiltration [2]. To overcome these barriers, we developed a precision nanovaccine (NV) targeting dendritic cells (DC). This strategy aims to enhance melanoma-immune cell interactions and broaden the range of targeted immune cells in a site-specific manner, offering a novel approach to improve outcomes.
Learning Objectives:
At the completion of this activity, participants will know
Unlock the potential of nanovaccines to improve the response rates of immune checkpoint inhibitors.
Understand the relevance of the intranasal route for brain tumors immune modulation.
Rita C Acúrcio, n/a – Junior Investigator, iMed.ULisboa - University of Lisbon, Lisbon, Portugal; Sabina Pozzi, n/a – Post Doc, Sackler Faculty of Medicine, Tel Aviv, Israel; Liane IF Moura, n/a – Junior Investigator, iMed.ULisboa - University of Lisbon, Lisbon, Portugal; Ana I Matos, n/a – Junior Investigator, iMed.ULisboa - University of Lisbon, Lisbon, Portugal; Ron Kleiner, n/a – PhD Student, Sackler Faculty of Medicine, Tel Aviv, Israel; Daniella Vaskovich-Koubi, n/a – PhD Student, iMed.ULisboa - University of Lisbon, Lisbon, Portugal; Adelaide Fernandes, n/a – Professor, iMed.ULisboa - University of Lisbon, Lisbon, Portugal; Sara Xapelli, n/a – Professor, GIMM, University of Lisbon, Lisbon, Portugal; Ronit Satchi-Fainaro, n/a – Professor, Sackler Faculty of Medicine, Tel Aviv, Israel; Helena F Florindo, n/a – Professor, iMed.ULisboa - University of Lisbon, Lisbon, Portugal
